ROS-Responsive Nanoplatforms for Targeted Tumor Immunomodulation: A Paradigm Shift in Precision Cancer Immunotherapy

Area of Science:

• Biomedical Engineering
• Immunology
• Oncology

Background:

• The immunosuppressive tumor microenvironment (TME) limits cancer immunotherapy efficacy in solid tumors.
• Reactive oxygen species (ROS) play a dual role in the TME, influencing immunogenic cell death (ICD) and immune cell function.
• Nano-enabled drug delivery systems offer advantages for TME modulation, including targeted delivery and controlled release.

Purpose of the Study:

• To review recent advancements in ROS-responsive nanosystems for antitumor immunotherapy.
• To explore the mechanistic interplay between these nanosystems and TME components.
• To assess the clinical translation potential of ROS-responsive nanoplatforms.

Main Methods:

• Comprehensive literature review of ROS-responsive nanosystems in cancer immunotherapy.
• Analysis of studies focusing on TME modulation and immune cell reprogramming.
• Examination of synergistic effects with conventional therapies like chemotherapy, radiotherapy, and photodynamic therapy (PDT).

Main Results:

• ROS-responsive nanoplatforms can restore ICD and remodel immunosuppressive immune cells within the TME.
• These nanoplatforms enhance conventional cancer therapies through ROS-mediated sensitization.
• Integrated therapeutic strategies utilizing ROS-responsive nanosystems show promise for overcoming immunotherapy limitations.

Conclusions:

• ROS-responsive nanoplatforms represent a promising strategy for enhancing cancer immunotherapy by targeting the TME.
• Further research into their mechanistic interplay and clinical translation is warranted.
• Developing integrated therapeutic approaches is crucial for improving outcomes in solid tumor treatment.